Sirolimus and non-melanoma skin cancer prevention after kidney transplantation: A meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 9, 2012, Pages 4335-4339

  Gu, Yu Hong ^a   Du, Jia Xin ^a   Ma, Man Ling ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Kidney transplantation; Meta analysis; Non melanoma skin cancer; Sirolimus

Indexed keywords

EID: 84874012869     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.9.4335     Document Type: Article

References (32)

1. Alberu J, Pascoe MD, Campistol JM, et al (2011). Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation, 92, 303-10.
2. Campbell SB, Walker R, Tai SS, et al (2012). Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant, 12, 1146-56.
3. Campistol JM, Eris J, Oberbauer R, et al (2006). Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol, 17, 581-9.
4. Cochran WG (1954). The combination of estimates from different experiments. Biometrics, 10, 101-29.
5. Dantal J, Soulillou JP (2005). Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med, 352, 1371-3.
6. de Gruijl FR, Koehl GE, Voskamp P, et al (2010). Early and late effects of the immunosuppressants rapamycin and mycophenolate mofetil on UV carcinogenesis. Int J Cancer, 127, 796-804.
7. De Luca A, Maiello MR, D'Alessio A, et al (2012). The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets, 16, S17-27.
8. De Masson A, Fouchard N, Mery-Bossard L, et al (2011). Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors. Dermatology, 223, 4-8.
9. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
10. Euvrard S, Kanitakis J, Claudy A (2003). Skin cancers after organ transplantation. N Engl J Med, 348, 1681-91.
11. Euvrard S, Morelon E, Rostaing L, et al (2012). Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med, 367, 329-39.
12. Flechner SM, Glyda M, Cockfield S, et al (2011). The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant, 11, 1633-44.
13. Guba M, Graeb C, Jauch KW, et al (2004). Pro- and anticancer effects of immunosuppressive agents used in organ transplantation. Transplantation, 77, 1777-82.
14. Guyatt GH, Oxman AD, Vist GE, et al (2008). GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 336, 924-6.
15. Halloran PF (2004). Immunosuppressive drugs for kidney transplantation. N Engl J Med, 351, 2715-29.
16. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.
17. Higgins JP, Altman DG, Gotzsche PC, et al (2011). The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343, d5928.
18. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
19. Meguid El Nahas A, Bello AK (2005). Chronic kidney disease: the global challenge. Lancet, 365, 331-40.
20. Nankivell BJ, Alexander SI (2010). Rejection of the kidney allograft. N Engl J Med, 363, 1451-62.
21. Nankivell BJ, Kuypers DR (2011). Diagnosis and prevention of chronic kidney allograft loss. Lancet, 378, 1428-37.
22. Petitti DB, 2000. Meta-analysis, decision analysis, and cost effectiveness analysis: methods for quantitative synthesis in medicine(2nded). Vol., New York, NY: Oxford University Press.
23. Russell LB, Gold MR, Siegel JE, et al (1996). The role of costeffectiveness analysis in health and medicine. JAMA, 276, 1172-7.
24. Salgo R, Gossmann J, Schofer H, et al (2010). Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant, 10, 1385-93.
25. Schena FP, Pascoe MD, Alberu J, et al (2009). Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation, 87, 233-42.
26. Serra AL, Poster D, Kistler AD, et al (2010). Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med, 363, 820-9.
27. Simmonds MC, Higgins JP, Stewart LA, et al (2005). Metaanalysis of individual patient data from randomized trials: a review of methods used in practice. Clin Trials, 2, 209-17.
28. Sun Q, Li X, Cheng D, et al (2011). Special malignancy pattern in Chinese renal transplantation recipients: a single center experience and literature review. Asian Pac J Cancer Prev, 12, 3347-51.
29. Traywick C, O'Reilly FM (2005). Management of skin cancer in solid organ transplant recipients. Dermatol Ther, 18, 12-8.
30. Wisgerhof HC, Edelbroek JR, de Fijter JW, et al (2010). Subsequent squamous- and basal-cell carcinomas in kidneytransplant recipients after the first skin cancer: cumulative incidence and risk factors. Transplantation, 89, 1231-8.
31. Wu C, Shapiro R (2011). Post-transplant malignancy: reducing the risk in kidney transplant recipients. Expert Opin Pharmacother, 12, 1719-29.
32. Yunus M, Aziz T, Mubarak M (2012). Posttransplant malignancies in renal transplant recipients: 22-years experience from a single center in Pakistan. Asian Pac J Cancer Prev, 13, 575-8.